Kythera Biopharmaceuticals' Drug Successfully Reduces Double Chin in Studies
Published: Sep 19, 2013
Kythera Biopharmaceuticals Inc said its experimental injectable drug succeeded in reducing double chin of patients in late-stage studies, meeting the main and secondary goals of two clinical trials. The company's shares jumped 10 percent on the positive data for its lead drug, ATX-101. Over 1000 patients with moderate to severe submental fat were tested in the two studies conducted in the United States and Canada, where ATX-101 was evaluated against a placebo.
Help employers find you! Check out all the jobs and post your resume.